Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 80, Issue 4, 2011, Pages 1064-1071

  Krauss, Daniel ^a,b   Kestin, Larry ^a   Ye, Hong ^a   Brabbins, Donald ^a   Ghilezan, Michel ^a   Gustafson, Gary ^a   Vicini, Frank ^a   Martinez, Alvaro ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

Androgen deprivation; Dose escalation; Prostate cancer

Indexed keywords

ANDROGEN DEPRIVATION; ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL CONTROL; BRACHYTHERAPY; CLINICAL FAILURE; DOSE ESCALATION; GLEASON SCORES; HIGH-DOSE RATE BRACHYTHERAPY; HIGH-RISK PATIENTS; LOW DOSE RATE; PROSPECTIVE STUDY; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN;

ONCOLOGY; PATIENT MONITORING; RADIOTHERAPY;

DISEASES;

PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE SEVERITY; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL RATE; TREATMENT FAILURE;

AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79959331135     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.04.004     Document Type: Article

References (30)

1. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A Phase III randomized trial Lancet 360 2002 103 108 (Pubitemid 34786197)
2. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 22 2003 3972 3978 (Pubitemid 46606211)
3. M.V. Pilepich, K. Winter, and M.J. John Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252 (Pubitemid 32727802)
4. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of Phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290 (Pubitemid 40470408)
5. A.V. D'Amico, J. Manola, and M. Loffredo 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial JAMA 292 2004 821 827 (Pubitemid 39079668)
6. J.W. Denham, A. Steigler, and D.S. Lamb Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial Lancet Oncol 6 2005 841 850 (Pubitemid 41614795)
7. J. Laverdiere, N. Abdenour, and L. Diaz de Bedoya The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer J Urol 171 2004 1137 1140 (Pubitemid 38327543)
8. M. Bolla, T.M. Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
9. J.M. Michalski, K. Winter, and J.A. Purdy Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level V Int J Radiat Oncol Biol Phys 62 2005 706 713 (Pubitemid 40779758)
10. J.M. Michalski, K. Winter, and J.A. Purdy Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV Int J Radiat Oncol Biol Phys 58 2004 735 742
11. J.K. Ryu, K. Winter, and J.M. Michalski Preliminary report of toxicity following 3D conformal radiation therapy (3D CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy) Int J Radiat Oncol Biol Phys 51 2001 136 137
12. M.J. Zelefsky, Z. Fuks, and L. Happersett Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer Radiother Oncol 55 2000 241 249 (Pubitemid 30408370)
13. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M.D. Anderson randomized dose escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74 (Pubitemid 350251041)
14. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial JAMA 294 2005 1233 1239 (Pubitemid 41352111)
15. S. Peeters, W.D. Heemsbergen, and P. Koper Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized Phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996 (Pubitemid 46622106)
16. M.J. Zelefsky, Y. Yamada, and Z. Fuks Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes Int J Radiat Oncol Biol Phys 71 2008 1028 1033
17. J.L. Speight, and M. Roach Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies, and new directions J Clin Oncol 23 2005 8176 8185 (Pubitemid 46211552)
18. C. Vargas, D. Yan, and L.L. Kestin Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: Use of dose-volume constraints to achieve rectal isotoxicity Int J Radiat Oncol Biol Phys 63 2005 141 149 (Pubitemid 41583552)
19. D. Brabbins, A. Martinez, and D. Yan A dose escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: Analysis of chronic toxicity Int J Radiat Oncol Biol Phys 61 2005 400 408 (Pubitemid 40164433)
20. A.A. Martinez, D. Yan, and D. Lockman Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer Int J Radiat Oncol Biol Phys 50 2001 1226 1234 (Pubitemid 32727800)
21. A. Martinez, G. Gustafson, and J. Gonzalez Dose escalation using conformal high dose rate brachytherapy improves outcome in unfavorable prostate cancer Int J Radiat Oncol Biol Phys 53 2002 316 327 (Pubitemid 34522097)
22. A. Martinez, J. Gonzalez, and J. Stromberg Conformal prostate brachytherapy: Initial experience of a Phase I/II clinical trial Int J Radiat Oncol Biol Phys 33 1995 1019 1027
23. J. Stromberg, A. Martinez, and J. Gonzalez Ultrasound-guided conformal high dose rate brachytherapy boost in prostate cancer: Treatment description and preliminary results of a Phase I/II clinical trial Int J Radiat Oncol Biol Phys 33 1995 161 171
24. E. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
25. D.R. Cox Regression models and life tables J R Stat Soc B 34 1972 187 220
26. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
27. G.S. Merrick, W.M. Butler, and K.E. Wallner Androgen deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 65 2006 669 677 (Pubitemid 43795860)
28. D.C. Beyer, T. McKeough, and T. Thomas Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 61 2005 1299 1305
29. A.A. Martinez, D.J. Demanes, and R. Galalae Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime Int J Radiat Oncol Biol Phys 62 2005 1322 1331 (Pubitemid 40982050)
30. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)